Apollo Endosurgery, Inc. (NASDAQ:APEN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The brokerage presently has a $4.75 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 15.29% from the stock’s current price.

According to Zacks, “Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company’s product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. “

A number of other equities research analysts have also recently issued reports on APEN. Northland Securities reaffirmed a “buy” rating on shares of Apollo Endosurgery in a research note on Friday, October 27th. ValuEngine lowered shares of Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Roth Capital started coverage on shares of Apollo Endosurgery in a report on Wednesday, August 2nd. They set a “buy” rating and a $10.00 price target for the company. Finally, Craig Hallum started coverage on shares of Apollo Endosurgery in a report on Monday, July 24th. They set a “buy” rating and a $11.00 price target for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $9.44.

Apollo Endosurgery (NASDAQ:APEN) last announced its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.40). Apollo Endosurgery had a negative net margin of 62.31% and a negative return on equity of 98.11%. The business had revenue of $17.14 million during the quarter.

COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/02/apollo-endosurgery-inc-apen-lifted-to-buy-at-zacks-investment-research.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Get a free copy of the Zacks research report on Apollo Endosurgery (APEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.